Jonathan Rosenberg joins Alicia Morgans to discuss long-term outcomes of enfortumab vedotin (EV) in patients with previously treated advanced urothelial carcinoma (UC) in the EV-301 trial. The EV-301 trial demonstrated improvements in progression-free and overall survival for patients with previously treated advanced UC who received EV compared to chemotherapy. In discussing how this updated analysis affects his practice, Dr. Rosenburg shares that it gives him the ability to talk to patients about long-term outcomes in advanced disease, where we really unfortunately still have relatively low numbers of patients making it to five years. He also highlights that this data confirms the toxicity profile of the drug. In closing the pair discusses where we see enfortumab vedotin going in the future.

Biographies:

Jonathan E. Rosenberg, MD, Chief of the Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology; and the Enno W. Ercklentz Chair at Memorial Sloan Kettering Cancer Center, New York City, New York

Alicia Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts